Stock Market News

Amgen Inc. (AMGN) Completes Phase 3 Trial for ABP 206 Opdivo Biosimilar Candidate

wcc wcc
Mar 08, 2026 - 17:50
0 0
Amgen Inc. (AMGN) Completes Phase 3 Trial for ABP 206 Opdivo Biosimilar Candidate
Previous Article

3 Reasons Your Tax Refund Could Be Smaller in 2026 (and What To Do About It)

Next Article

The Coca-Cola Company (KO) Raises Annual Dividend for 64th Consecutive Year a...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Wow Wow 0
Sad Sad 0
Angry Angry 0
wcc
wcc

Related Posts

Could Bitcoin Become the World's Reserve Digital Currency?

Could Bitcoin Become the World's Reserve Digital Cur...

wcc
Jun 23, 2026
0
0
Kayne Anderson BDC (KBDC) Downgraded by Wells Fargo Amid Valuation Concerns

Kayne Anderson BDC (KBDC) Downgraded by Wells Fargo ...

wcc
Jun 23, 2026
0
0
Dollar General (DG) Raises Fiscal 2026 Outlook as Telsey Advisory Lowers Target

Dollar General (DG) Raises Fiscal 2026 Outlook as Te...

wcc
Jun 23, 2026
0
0
Autohome (ATHM) Faces Revenue Growth Challenges, Says Citi as Target Falls to $17

Autohome (ATHM) Faces Revenue Growth Challenges, Say...

wcc
Jun 23, 2026
0
0
Raymond James Cuts Northern Oil and Gas (NOG) Target but Backs Long-Term Production Growth

Raymond James Cuts Northern Oil and Gas (NOG) Target...

wcc
Jun 23, 2026
0
0
What Will ETFs Look Like in 2027? State Street Gazes into Its Crystal Ball

What Will ETFs Look Like in 2027? State Street Gazes...

wcc
Jun 23, 2026
0
0

Comments (0)

User